SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is trending due to a recent partnership with Semtech for AI and cloud network optical engines, sparking optimism about potential collaborations with major Semtech customers like Apple, Amazon, and Intel. The community is discussing the high trading volume and potential for a significant breakout, with some anticipating a short squeeze and long-term growth in the AI connectivity sector. Investors are also excited by the large 2027 call option volume, possibly indicating a large long term position is being built.

Galecto, Inc. is a clinical-stage biotechnology company, which engages in developing novel small molecule therapeutics that are designed to target the biological processes that lie at the heart of cancer and fibrotic diseases. The firm is also involved in the development of small molecule inhibitors of galectin-3 and LOXL2. The company was founded by Ulf Jörgen Nilsson, Hakon Leffler, Tariq Sethi, and Hans Thalsgård Schambye in 2011 and is headquartered in Boston, MA.

Galecto Inc

Galecto (GLTO) is experiencing significant volatility, driven by a high short interest and low float, leading to a battle between bulls anticipating a short squeeze and bears predicting a crash. The community is actively debating potential price targets and whether it can emulate similar runs seen in other stocks. This action is occurring without any specific news catalyst, contributing to the speculative nature of the trading activity.

N2OFF, Inc. is a clean tech company engaged in sustainable solutions for energy and innovation for agri- tech. It delivers integrated solutions for sustainable energy, greenhouse gas emissions reduction and safety, quality solutions for the agri- tech market. Its products include SpuDefender and FreshProtect. The SpuDefender is designed to control the post-harvest potato sprout. The FreshProtect is designed to control spoilage-creating microorganisms on post-harvest citrus fruit. The firm operates through the following segments: Pathogen prevention and prolong shelf life and N2O emissions Global warming solutions. N2OFF was founded by Nimrod Ben-Yehuda on April 1, 2009 and is headquartered in Neve Yarak, Israel.

N2OFF Inc.

NITO is trending due to community discussion around a potential merger and its low float, which some believe could lead to a significant short squeeze. Traders are actively discussing potential catalysts and technical indicators, hoping for a breakout. Community members are highlighting the stock's volatility and comparing it to other recent nano-float runners.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is trending as investors discuss its AI cloud services and potential for significant growth in the AI data center market. Community members are highlighting the company's multi-year contracts, revenue projections, and strategic shift from Bitcoin mining to AI infrastructure. Some analysts have given IREN a high price target, contributing to the positive sentiment.

NuCana Plc is a clinical stage biopharmaceutical company. It engages in the business of developing a portfolio of new medicines to treat patients with cancer. The company was founded by Hugh Stephen Griffith and Christopher Barry Wood on January 28, 1997 and is headquartered in Edinburgh, the United Kingdom.

NuCana plc - ADR

NuCana plc

NuCana ($NCNA) is trending due to renewed interest in its low float and upcoming data presentation at the ESMO Congress in October, sparking speculation of a potential squeeze. The community is drawing comparisons to other low-float runners and highlighting the company's strong cash runway into 2029. Some investors are also pointing to a recently published research article as a potential catalyst.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending as the community rallies around its vision of natural wellness and plant-based healing, contrasting with traditional pharmaceuticals. Community members are sharing links to the Weedcoin website and highlighting its connection to cannabis culture. The coin aims to promote accessibility and normalize natural medicine.

Trilogy Metals, Inc. engages in the development and exploration of mineral properties. The firm holds interests in the Upper Kobuk mineral projects that include the Arctic, a copper-zinc-lead-gold-silver and Bornite, a carbonate-hosted copper projects, which is located in the Ambler mining district in Northwest Alaska. The company was founded on April 27, 2011 and is headquartered in Vancouver, Canada.

Trilogy Metals Inc

Trilogy Metals is trending following news of a significant U.S. government investment, sparking discussions of a potential short squeeze and future double-digit prices. The community is weighing the implications of government involvement and potential catalysts. This activity occurs amid a broader focus on securing domestic mineral resources.

TMC the metals co., Inc. is a deep-sea minerals exploration company focused on the collection and processing of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone in the Pacific Ocean (CCZ). These nodules contain high grades of four metals (nickel, copper, cobalt, manganese) which can be used as (i) feedstock for battery cathode precursors (nickel, cobalt and manganese sulfates, or intermediate nickel-copper-cobalt matte) for electric vehicles (EV) and renewable energy storage markets, (ii) copper cathode for EV wiring, energy transmission and other applications and (iii) manganese silicate for manganese alloy production required for steel production. The company was founded in 2021 and is headquartered in Vancouver, Canada.

TMC the metals company Inc

$TMC is trending amid renewed interest in deep-sea mining, with investors closely watching for potential government partnerships and regulatory approvals, especially regarding the NOAA decision. The community is actively discussing the possibility of a short squeeze and the stock's breakout potential. Bullish sentiment is driven by the company's long-term prospects in the critical minerals market.

Churchill Capital Corp. X is a blank check company, which was created for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded by Michael Klein on January 4, 2024 and is headquartered in New York, NY.

Churchill Capital Corp X - Ordinary Shares - Class A

Churchill Capital Corp X 

Churchill Capital Corp X ($CCCX) is trending as chatter increases around its merger with quantum computing company Infleqtion. The community highlights Infleqtion's existing contracts, partnership with NVIDIA, and potential for growth compared to sector peers like $IONQ and $RGTI. Some investors believe $CCCX is currently undervalued and presents a compelling entry point into the quantum computing space.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class C

GOOG is trending amid discussions around its AI initiatives, particularly the Gemini model, and its potential impact on competition with companies like OpenAI. Community members are weighing the stock's valuation and growth prospects, with some pointing to its dominance in search and other areas. Additionally, developments in its Waymo robotaxi service and partnerships in the AI infrastructure space are sparking interest.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

FDA Approves Label Extension of REGN's Cholesterol Drug Evkeeza 

Regeneron wins FDA approval to extend Evkeeza use in children as young as one with severe familial hypercholesterolemia.

SNY & REGN's Dupixent Receives CHMP Backing for Urticaria in EU

Sanofi/Regeneron's Dupixent wins CHMP backing for chronic spontaneous urticaria in the EU, paving the way for expanded treatment options.

NTLA Completes Enrollment in Pivotal Study on HAE Candidate, Stock Up

Intellia shares surge nearly 30% as the company completes enrollment in its pivotal phase III HAELO study on lonvo-z for hereditary angioedema.

REGN Loses 21.1% Year to Date: Buy, Sell or Hold the Sock?

Regeneron shares slump as Eylea struggles, but Dupixent gains and a strengthening oncology pipeline offer growth potential.

Strength Seen in Travere (TVTX): Can Its 26.2% Jump Turn into More Strength?

Travere (TVTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

NKTR Shares Surge 38.2% in a Week: Here's What You Should Know

Nektar shares surge 38.2% on investor optimism on rezpeg's potential in atopic dermatitis after upbeat mid-stage study results.

Regeneron Pharmaceuticals, Inc. (REGN) said on Monday that its experimental therapy significantly reduced symptoms of cat and birch allergies in late-stage trials, successfully meeting their key endpoints.In the <a target="_blank" rel="noopener noreferrer nofollow" href="https://investor.regeneron.com/news-releases/news-release-details/regeneron-advances-allergy-pipeline-two-positive-phase-3-trials">trials</a>, patients with moderate to severe cat or birch allergies received direct instillation of either cat dander or birch pollen into the eyes, followed by a single subcutaneous administration of the allergen-blocking antibodies. The antibody blockers “significantly reduced” allergy symptoms compared to placebo, the company said.The company stated that the data from the studies will be presented at an upcoming medical conference and used to inform confirmatory late-stage trials. Both the cat and birch allergy programs are part of a broader allergy pipeline, which includes an ongoing study in adults with severe food allergy. Initial results from the food allergy trial have been encouraging, the company said on Monday.Regeneron Chief Scientific Officer George D. Yancopoulos stated on Monday that the company anticipates significant relief at the earliest assessment time point, which is expected to last over three months, in both our cat and birch allergy programs.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/REGN">REGN stock</a> fell from ‘bullish’ to ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘low’ levels. Shares of the company traded 1% higher in the pre-market session at the time of writing.Yancopoulos said that while millions suffer from the effects of allergies, most undergo allergy desensitization shots, often with disappointing results.“The purpose of these burdensome allergy shots is to try to build up allergen-blocking antibodies in the body. We wondered whether we could instead manufacture and directly provide allergen-blocking antibodies,” he said. “These recent Phase 3 allergen challenge trials, together with our earlier Phase 2 trials, provide compelling evidence that our first-in-class approach can have the potential to provide profound allergy relief – rapidly and durably after a single treatment – decreasing ocular, nasal and even asthma measures.”Regeneron noted that Birch pollen is one of the most common seasonal allergens in the U.S., affecting more than 10 million people, while cat allergy affects more than 20 million people. In the trials, patients received a combination of two antibody blockers or a placebo. Those who received the combination had fewer allergy symptoms, such as conjunctival redness.While additional late-stage trials in cat allergy are planned to begin in the first half of 2026, further late-stage development in birch allergy is expected to commence by the end of the year.REGN stock is down by 20% this year and by about 50% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/echostar-to-dell-17-billion-in-spectrum-assets-to-spacex/chwWH3JRdAD">EchoStar To Sell $17B In Spectrum Assets To SpaceX – Stock Rockets 40% Pre-Market</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.Get updates to this developing story <a href="https://stocktwits.com/news-articles/markets/equity/regeneron-says-experimental-therapy-reduced-symptoms-of-cat-birch-allergies-in-studies/chwWH37RdAw">directly on Stocktwits.</a>

In this photo illustration, the Regeneron Pharmaceuticals company logo is displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Regeneron Says Experimental Therapy Reduced Symptoms Of Cat, Birch Allergies In Late-Stage Trials

The company said that the antibody blockers “significantly reduced” allergy symptoms compared to a placebo in the trials. 

Equity

The company said that the antibody blockers “significantly reduced” allergy symptoms compared to a placebo in the trials. 


RHHBY Posts Positive Data on Vabysmo in nAMD at Euretina Congress 

Roche posts strong new data for Vabysmo in eye disease, with extended dosing and vision gains driving growth.

SNY Down Despite Eczema Candidate Meeting Goal in Phase III Study

Sanofi shares fall despite phase III success for eczema drug candidate, amlitelimab, showing strong efficacy and safety in patients.

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

REGN Regeneron Pharmaceuticals, Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest REGN News